A high-carbohydrate diet enhances the adverse effect of the S2 allele of APOC3 SstI polymorphism on the TG/HDL-C ratio only in young Chinese females

Braz J Med Biol Res, June 2011, Volume 44(6) 524-530

A high-carbohydrate diet enhances the adverse effect of the S2 allele of APOC3 SstI polymorphism on the TG/HDL-C ratio only in young Chinese females

Yong Yan Song¹, Ren Rong Gong², Zhen Zhang¹, Yuan Hao Li¹, Li Ying Xiao¹, Xue Dong Zhou¹ and Ding Zhi Fang¹

¹Department of Biochemistry and Molecular Biology, West China School of Preclinical and Forensic Medicine, and State Key Laboratory of Oral Diseases, Sichuan University, Chengdu, China

²Department of Cardiothoracic Surgery, West China Hospital, Sichuan University, Chengdu, China

^{Correspondence and Footnotes}

Abstract

Both genetic background and diet have profound effects on plasma lipid profiles. We hypothesized that a high-carbohydrate (high-CHO) diet may affect the ratios of serum lipids and apolipoproteins (apo) differently in subjects with different genotypes of the SstI polymorphism in the apoCIII gene (APOC3). Fifty-six healthy university students (27 males and 29 females, 22.89 ± 1.80 years) were given a washout diet of 54% carbohydrate for 7 days, followed by a high-CHO diet of 70% carbohydrate for 6 days without total energy restriction. Serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apoB100, apoAI, and the APOC3 SstI polymorphism were analyzed. The ratios of serum lipids and apoB100/apoAI were calculated. At baseline, the TG/HDL-C ratio was significantly higher in females, but not in males, with the S2 allele. The differences in the TG/HDL-C ratio between genotypes remained the same after the washout and the high-CHO diet in females. When compared with those before the high-CHO diet, the TC/HDL-C (male S2 carriers: 3.13 ± 1.00 vs 2.36 ± 0.65, P = 0.000; male subjects with the S1S1 genotype: 2.97 ± 0.74 vs 2.09 ± 0.55, P = 0.000; female S2 carriers: 2.68 ± 0.36 vs 2.24 ± 0.37, P = 0.004; female subjects with the S1S1 genotype: 2.69 ± 0.41 vs 2.09 ± 0.31, P = 0.000) and LDL-C/HDL-C (male S2 carriers: 1.44 ± 0.71 vs 1.06 ± 0.26, P = 0.012; male subjects with the S1S1 genotype: 1.35 ± 0.61 vs 1.01 ± 0.29, P = 0.005; female S2 carriers: 1.18 ± 0.33 vs 1.00 ± 0.18, P = 0.049; female subjects with the S1S1 genotype: 1.18 ± 0.35 vs 1.04 ± 0.19, P = 0.026) ratios were significantly decreased after the high-CHO diet regardless of gender and of genotype of the APOC3 SstI polymorphism. However, in female S2 carriers, the TG/HDL-C (1.38 ± 0.46 vs 1.63 ± 0.70, P = 0.039) ratio was significantly increased after the high-CHO diet. In conclusion, the high-CHO diet has favorable effects on the TC/HDL-C and LDL-C/HDL-C ratios regardless of gender and of genotype of the APOC3 SstI polymorphism. Somehow, it enhanced the adverse effect of the S2 allele on the TG/HDL-C ratio only in females.

Key words: High-carbohydrate diet; Lipid ratio; Gene polymorphism; Human APOC3

Introduction

Cardiovascular disease (CVD) is recognized as a multifactorial disease, and dyslipidemia accounts for at least 50% of the population-attributable risk (1). Reliable indexes for CVD risk assessment and targets for drug treatment are important to prevent and manage this disease. Conventionally, increases in plasma total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and/or triglyceride (TG) and decreases in high-density lipoprotein cholesterol (HDL-C) were considered to be the major factors causing CVD (2). Clinical guidelines recommended that the primary therapy be targeted to LDL-C reduction, and that the other lipid indexes be used as the secondary or supplementary targets (2). However, accumulating evidence from epidemiological and precisely controlled studies suggests that the HDL-C-related ratios including TG/HDL-C, TC/HDL-C and LDL-C/HDL-C may be superior to conventional lipid parameters as predictors of CVD or therapeutic targets for dyslipidemia (3-6). As the TC/HDL-C ratio is considered to be a more sensitive and predictive index of cardiovascular risk than TC, the Canadian Vascular Society has chosen this lipid ratio as a secondary goal of therapy (7). Recent data from observational and interventional studies have suggested that the apolipoprotein B100/apolipoprotein AI (apoB100/apoAI) ratio may be another strong and new CVD marker that is even better than the HDL-C-related ratios in CVD risk assessment (8-10). Each particle of the atherogenic lipoproteins, such as LDL, very low-density lipoprotein (VLDL) and intermediate-density lipoprotein, carries one apoB molecule, so that the concentrations of serum apoB reflect the total atherogenic potentials. On the other hand, apoAI is the major protein component of antiatherogenic lipoprotein, i.e., HDL, and the serum content of apoAI represents the total antiatherogenic potential. Thus, the apoB/apoAI ratio could be a comprehensive and accurate CVD risk maker; the lower the apoB/apoAI ratio, the lower the risk.

A high-carbohydrate (high-CHO) diet has profound effects on lipid metabolism. Carbohydrates can be converted into fatty acids, TG, cholesterol, and other lipids in the liver and other organs. Previous studies have demonstrated that a high-CHO diet could increase fasting serum TG concentrations (11,12), leading to hypertriglyceridemia, a risk factor of CVD (13). It has also been documented that a high-CHO diet could decrease the risk of CVD by lowering plasma TC and LDL-C concentrations (12). Although the effects of a high-CHO diet on the changes of TC, LDL-C, HDL-C, and TG have been extensively reported in the past several decades, few reports are available about the effects of a high-CHO diet on the HDL-C-related and apoB100/apoAI ratios in subjects with different genotypes of the apolipoprotein gene polymorphisms. Since Chinese populations are accustomed to consuming carbohydrate-enriched diets (14,15), it is necessary to investigate the plasma lipid responses of subjects with a specific genetic background to the high-CHO diets.

ApoCIII plays an important role in the regulation of the metabolism of triglyceride-rich lipoproteins (TRLs) (16). Some polymorphisms in the apoCIII gene (APOC3) locus have been found to be closely related to plasma TG concentrations (17-19). The SstI polymorphism is formed by a transversion from C to G and is located in the 3’ untranslated region (3’UTR) of this gene (20). A number of studies have reported that the S2 carriers of the APOC3 SstI polymorphism had higher plasma levels of TG (21-26), TC (27,28), LDL-C (27), and lower levels of HDL-C (27). The S2 allele was also associated with elevated plasma concentrations of apoCIII (29,30) and apoB (27,29,30), but not with lower apoAI levels (29). However, the interaction of this polymorphism with the high-CHO diet on serum lipid ratios has not been reported before.

Previous studies have shown that both the high-CHO diet and the APOC3 SstI polymorphism affect the serum lipid and lipoprotein profiles (11,12,21-30). Therefore, we supposed that the different genotypes of the APOC3 SstI polymorphism may have different responses to the high-CHO diet regarding the ratios of serum lipids and apolipoproteins. In the present study, we investigated the interaction of a high-CHO diet with the APOC3 SstI polymorphism on the ratios of serum lipids and apolipoproteins in a young and healthy Chinese population. This may provide experimental evidence for the personalized dietary recommendations in the country with the largest population in the world.

Subjects and Methods

Subjects and diets

A total of 209 university students were recruited as volunteers by advertisement from West China Medical Center, Sichuan University. All were Chinese Han people. Before the dietary intervention, all volunteers completed a medical questionnaire and were subjected to a physiological and biochemical examination. According to the results of the medical survey and physiological and biochemical examination, those who met the inclusion criteria finally entered the study. These criteria included no history of metabolic diseases, understanding of the procedures involved, and providing written consent. Exclusion criteria were: presence of diabetes, dyslipidemia, or cardiovascular, renal, endocrinologic diseases, taking lipid-lowering drugs or hormones, consuming alcohol, smoking, or wide variation in physical activity or sleeping time. Finally, 60 volunteers, who were apparently healthy as indicated by the medical questionnaire and the physiological and biochemical examination, entered the study. Fifty-six subjects (27 males and 29 females) completed the study with good compliance to the end; their baseline characteristics are shown in Table 1.

In the present study, a 13-day dietary intervention included 7 days of the washout diet as a washout period and 6 days of the high-CHO diet. Previous studies (31) have indicated that serum lipids could reach a new steady state after 5 days of dietary intervention. Therefore, a regime of 7 days of washout control diet followed by 6 days of high-CHO intervention diet was adopted in this study. As shown in Table 2, the washout diet contained 54% carbohydrate, 31% fat, and 15% protein, and the high-CHO diet contained 70% carbohydrate, 15% fat, and 15% protein of the total energy. The ingredients of the meals were from foods consumed by local people daily and all meals were prepared by the Department of Nutrition, West China Hospital, Sichuan University. Three daily meals were given to the volunteers who always ate together in a group at the student canteen at Huaxi campus of Sichuan University. The offered meals were breakfast at 7:00 to 8:00 am, lunch at 11:30 to 12:30, and dinner at 5:00 to 6:00 pm. The composition of each meal changed every day, but each meal had constant ratios of carbohydrate, protein, and fat as part of total energy. A daily dietary log was used to assess the compliance of each participant to the dietary intervention. There was no total energy restriction. Calories from food intake were not restricted for each meal. The volunteers ordered their meals according to their estimations of how much they needed to eat for satiation as usual in their daily life. However, subjects were instructed not to take any other food or drink, except water. The study protocol was approved by the Human Research Ethics Committee of Sichuan University (No. 3011011).

Measurements of serum lipids and apolipoproteins

On the mornings of the day when the washout diet was started, of the day when the high-CHO diet was started and of the day after the high-CHO diet, 12-h fasting venous blood samples were collected. Serum was prepared by centrifugation at 3000 g for 15 min and immediately used for the measurement of serum lipids and apolipoproteins. Enzymatic methods were used to determine the serum concentrations of TG and TC. HDL-C concentrations were measured after precipitation of apoB-containing lipoproteins with phosphotungstic-Mg²⁺ (Biosino, China). LDL-C concentrations were determined by the polyvinyl sulfate (Biosino) precipitation method using a semi-automated biochemistry analyzer BT-224 (Biotecnica, Italy). Immunoturbidimetry assays were used to determine the serum levels of apoB100 and apoAI. All biochemical parameters were measured three times, and the mean value of the three measurements was used for the calculation of the ratios of serum lipids and apolipoproteins.

DNA extraction and genotyping

Genomic DNA was isolated from peripheral blood leukocytes using a DNAout kit (Tiandz, China). The DNA fragments containing the SstI site of APOC3 were amplified by PCR in a 25-µL reaction mixture containing 1 µL forward primer of 5’-GGTGACCGATG

GCTTCAGTTCCCTGA-3’ and 1 µL reverse primer of 5’-CAGAAGGTGG

ATAGAGCGCTGGCC-3’ (Sangon Biotech, China). The cycling conditions were 95°C for 5 min followed by 35 cycles of 95°C for 30 s, 58°C for 40 s, and 72°C for 40 s, with a final extension at 72°C for 5 min. One microliter PCR product was digested at 37°C for 16 h with 1 U SstI restriction enzyme (New England BioLabs, USA). Digested PCR products were analyzed on 2% agarose gel and visualized by ethidium bromide (GBC BIO-Tech, China) staining. The wild-type allele lacking the SstI cutting site was defined as S1, whose hydrolyte was an intact 428-bp DNA fragment, and the allele containing the SstI cutting site was defined as S2, whose hydrolytes were two DNA fragments of 308 and 120 bp.

Statistical analysis

Data are reported as means ± standard deviation (SD) unless otherwise stated. Normality of the data in each group was tested using the Shapiro-Wilk test. A log power transformation was applied to data with a positively skewed distribution (e.g., TG, TG/HDL-C). The genotype and allele frequencies were compared between males and females by the chi-square test. The mean values of the variables obtained before and after the high-CHO diet were compared by the paired t-test. The mean values of the variables were compared between different genotypes by one-way analysis of variance (ANOVA). The mean values of the variables were compared between males and females, or between males and females with the same genotype by the unpaired t-test. Statistical significance was defined at 0.05.

Results

Frequencies of genotypes and alleles of the APOC3 SstI polymorphism

Of the 56 subjects studied, 32 (57.1%) were wild-type homozygotes (S1S1), 20 (35.7%) were heterozygotes (S1S2), and 4 (7.1%) were mutant homozygotes (S2S2). The frequency of the major allele S1 was 75%, and the frequency of the minor allele S2 was 25%. No significant differences in genotype frequency (P = 0.189, χ² = 1.722) or allele frequency (P = 0.275, χ² = 1.192) were found between males and females. No deviation from the Hardy-Weinberg equilibrium was found in the distribution of the genotypes (P = 0.743, χ² = 0.107).

Baseline ratios of lipids and apolipoproteins according to the APOC3 SstI genotype

Due to the small group size of the homozygotes for the minor allele, the heterozygotes and homozygotes carrying the S2 allele were combined and referred to as the S2 carriers for statistical analysis. As shown in Table 3, there were no significant differences in the ratios between the S2 carriers and the subjects with the S1S1 genotype in the study population as a whole. When gender was taken into account, the female S2 carriers had a significantly higher ratio of TG/HDL-C (P = 0.009) than the females with the S1S1 genotype, whereas no significant associations were observed in males.

Effects of the high-carbohydrate diet on the ratios of serum lipids and apolipoproteins in the subjects with different genotypes of the APOC3 SstI polymorphism

As shown in Table 4, the S2 carriers had a significantly higher ratio of TG/HDL-C (P = 0.008) than the subjects with the S1S1 genotype after the high-CHO diet in the study population as a whole. Compared with those before the high-CHO diet, both TC/HDL-C (P = 0.000 for both the S2 carriers and the subjects with the S1S1 genotype) and LDL-C/HDL-C (P = 0.002 for the S2 carriers and P = 0.000 for the subjects with the S1S1 genotype) decreased significantly after the high-CHO diet regardless of genotype. TG/HDL-C (P = 0.011) increased and apoB100/apoAI (P = 0.006) decreased significantly only in the S2 carriers.

When gender was taken into account, the females with the S1S1 genotype had a significantly lower ratio of TG/HDL-C (P = 0.013) than the males with the same genotype before the high-CHO diet. The female S2 carriers had a higher ratio of TG/HDL-C than the females with the S1S1 genotype before (P = 0.016) or after (P = 0.013) the high-CHO diet. When compared with those before the high-CHO diet, both TC/HDL-C (P = 0.000 for both the male S2 carriers and the male subjects with the S1S1 genotype; P = 0.004 for the female S2 carriers and P = 0.000 for the female subjects with the S1S1 genotype) and LDL-C/HDL-C (P = 0.012 for the male S2 carriers, P = 0.005 for the male subjects with the S1S1 genotype, P = 0.049 for the female S2 carriers, and P = 0.026 for the female subjects with the S1S1 genotype) decreased significantly after the high-CHO diet regardless of gender or genotype of the APOC3 SstI polymorphism. A significant elevation of TG/HDL-C (P = 0.039) was observed only in the female carriers of the S2 allele and a significant reduction of apoB100/apoAI (P = 0.012) was observed only in the male carriers of the S2 allele after the high-CHO diet intervention.

Table 1.
Anthropometric and biochemical characteristics of the study subjects.

Table 2.
Composition of the diets administered to the volunteers of the study as determined by chemical analysis.

Table 3.
Lipid and apolipoprotein ratios of the cohort at baseline.

Table 4.
Lipid and apolipoprotein ratios of the subjects before and after the high-carbohydrate (high-CHO) diet according to the APOC3 SstI genotype.

Discussion

ApoCIII is a major component of TRLs and has several functions in the regulation of the metabolism of TRLs. It inhibits the activities of lipoprotein lipase and hepatic lipase (32,33), two enzymes that metabolize TGs in TRLs and facilitate their clearance from the circulation. It impairs the hepatic uptake of TRL remnants, probably by interfering with the interaction of apoE in the lipoproteins with LDL receptors. Recent evidence has shown that apoCIII might stimulate VLDL assembly and secretion (34). Mutations at several loci have been found within or around the APOC3 gene. The most extensively studied one is the SstI polymorphism located in the 3’UTR of the gene (20). Associations of the minor allele S2 with higher levels of TG (21-26) and lower levels of HDL-C (27) have been reported in various ethnic groups. However, the interactions of this genetic variant with a high-CHO diet on the ratios of serum lipids and apolipoproteins have not been reported before. In the present study, the baseline level of TG/HDL-C of the S2 carriers was significantly higher than that of the subjects with the S1S1 genotype in females but not in males (Table 3). This result suggests that the SstI polymorphism in APOC3 is associated with the TG/HDL-C ratio and this association is gender-dependent. In addition, the TG/HDL-C ratio of the S2 carriers before or after the high-CHO diet was significantly higher than that of the subjects with the S1S1 genotype only in females but not in males (Table 4). These results indicate that the S2 allele of the SstI polymorphism in APOC3 is consistently associated with a higher TG/HDL-C ratio in females on different diets. On the other hand, the TG/HDL-C ratio in the females with the S1S1 genotype was significantly lower than that in the males with the same genotype after the washout diet. This result implies that, in the present study, the S1 allele had a favorable effect on the TG/HDL-C ratio in females on the washout diet.

The interactions of the SstI polymorphism in APOC3 with the high-CHO diet on the ratios of serum lipids and apolipoproteins of the subjects with different genotypes were also investigated in the present study. Conceivably, other genetic and environmental factors affecting lipoprotein metabolisms would remain constant for each individual, especially during such a short period of 6 days on the high-CHO diet. Therefore, the differences in changes of ratios upon the high-CHO diet intervention were most likely attributed to the specific genetic background of the individuals. The TG/HDL-C ratio after the high-CHO diet was significantly higher than that before the high-CHO diet only in the female carriers of the S2 allele but not in the females with the S1S1 genotype (Table 4). Considering the result that the TG/HDL-C ratio of the S2 carriers was consistently and significantly higher than that of the subjects with the S1S1 genotype only in the females before or after the high-CHO diet (Table 4), we may conclude that the high-CHO diet enhances the adverse effect of the S2 allele on the TG/HDL-C ratio in females.

To our knowledge, there are no published studies on the gender-dependent association of the SstI polymorphism in APOC3 with the TG/HDL-C ratio. However, several studies (26,27) have demonstrated that there were gender-dependent associations of the APOC3 SstI polymorphism with the plasma lipids, including TG, TC, HDL-C, LDL-C, and apoB. In a cohort study of American Caucasians, Russo et al. (27) reported that the S2 allele of the APOC3 SstI polymorphism was associated with lower concentrations of HDL-C and higher concentrations of TG only in males, indicating that the males with the S2 allele tended to have a higher TG/HDL-C ratio. Conversely, in a cohort study of Asian Taiwanese, Huang et al. (26) reported that the S2 allele of the APOC3 SstI polymorphism was associated with elevated TG only in females. Therefore, the females with this allele tended to have a higher TG/HDL-C ratio in this population. Taken together with the results of the present study, these data indicate that the association of the SstI polymorphism in APOC3 with the TG/HDL-C ratio is not only dependent on gender, but also on ethnicity.

One explanation for the fact that only females with the S2 allele of the SstI polymorphism in APOC3 were negatively influenced by the high-CHO diet could be their higher levels of estrogen. High-CHO diets can adversely increase the plasma concentrations of TGs (11,12), which are mainly hydrolyzed by lipoprotein lipase, the key enzyme in the hydrolysis of TGs in blood. However, high levels of estrogen in females significantly inhibit the activity of lipoprotein lipase and retard the hydrolysis of TGs by this enzyme (35).

Although previous investigators have reported that the S2 allele was associated with increased level of TC and decreased level of HDL-C (27,28), no significant differences were found in the TC/HDL-C and LDL-C/HDL-C ratios at baseline between S2 carriers and subjects with the S1S1 genotype. This result might be explained by the small sample size of 56 subjects and by the young age of the subjects (22.89 ± 1.80 years), since almost all previous studies were carried out on middle-aged or senior subjects (27,28). After the high-CHO diet, all subjects regardless of gender or genotype experienced significant decreases in the TC/HDL-C and LDL-C/HDL-C ratios determined before the diet. This may have been due to the fact that the marked decreases in the TC/HDL-C and LDL-C/HDL-C ratios after the high-CHO diet masked the effects of the genetic background and gender on the changes of the ratios in the young and healthy cohort. It is well known that the Chinese population is characterized by a lower incidence of CVD (36-38), more favorable lipid profiles including lower levels of TG, TC, and LDL-C and higher level of HDL-C, and a diet containing low fat and high carbohydrate (14,15). It is possible that the Chinese population has adapted to the high-CHO diet over the long time of biological evolution. Therefore, the TC/HDL-C and LDL-C/HDL-C ratios experienced marked decreases after a short-term high-CHO intake.

Favorable effects of the high-CHO diet were observed on the TC/HDL-C and LDL-C/HDL-C ratios regardless of gender or genotype of the APOC3 SstI polymorphism in a young and healthy Chinese cohort. However, the high-CHO diet enhanced the adverse effect of the S2 allele on the TG/HDL-C ratio in the females of this cohort. Our results may provide experimental evidence for personalized dietary recommendations in the country with the largest population in the world.

References

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.

2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.

3. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117: 3002-3009.

4. Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 2009; 5: 757-765.

5. Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 2004; 110: 2824-2830.

6. Hsia SH, Pan D, Berookim P, Lee ML. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol 2006; 98: 1047-1052.

7. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006; 22: 913-927.

8. Goswami B, Rajappa M, Mallika V, Kumar S, Shukla DK. Apo-B/apo-AI ratio: a better discriminator of coronary artery disease risk than other conventional lipid ratios in Indian patients with acute myocardial infarction. Acta Cardiol 2008; 63: 749-755.

9. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372: 224-233.

10. Liem AH, van de Woestijne AP, Roeters van Lennep HW, Zwinderman AH, van der Steeg WA, Jukema JW. ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients. Curr Med Res Opin 2008; 24: 359-364.

11. Parks EJ, Hellerstein MK. Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 2000; 71: 412-433.

12. Kasim-Karakas SE, Almario RU, Mueller WM, Peerson J. Changes in plasma lipoproteins during low-fat, high-carbohydrate diets: effects of energy intake. Am J Clin Nutr 2000; 71: 1439-1447.

13. Satoh H, Nishino T, Tomita K, Tsutsui H. Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men. Circ J 2006; 70: 227-231.

14. Lee MM, Wu-Williams A, Whittemore AS, Zheng S, Gallagher R, Teh CZ, et al. Comparison of dietary habits, physical activity and body size among Chinese in North America and China. Int J Epidemiol 1994; 23: 984-990.

15. Chen Z, Shu XO, Yang G, Li H, Li Q, Gao YT, et al. Nutrient intake among Chinese women living in Shanghai, China. Br J Nutr 2006; 96: 393-399.

16. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001; 12: 297-304.

17. Dallongeville J, Meirhaeghe A, Cottel D, Fruchart JC, Amouyel P, Helbecque N. Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. Atherosclerosis 2000; 150: 149-157.

18. Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 2008; 8: 228-236.

19. Hallman DM, Srinivasan SR, Chen W, Boerwinkle E, Berenson GS. Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study. Metabolism 2006; 55: 1574-1581.

20. Talmud PJ, Humphries SE. Apolipoprotein C-III gene variation and dyslipidaemia. Curr Opin Lipidol 1997; 8: 154-158.

21. Chhabra S, Narang R, Krishnan LR, Vasisht S, Agarwal DP, Srivastava LM, et al. Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC Genet 2002; 3: 9.

22. Ahn YI, Valdez R, Reddy AP, Cole SA, Weiss KM, Ferrell RE. DNA polymorphisms of the apolipoprotein AI/CIII/AIV gene cluster influence plasma cholesterol and triglyceride levels in the Mayans of the Yucatan Peninsula, Mexico. Hum Hered 1991; 41: 281-289.

23. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 1993; 100: 157-169.

24. Ko YL, Ko YS, Wu SM, Teng MS, Chen FR, Hsu TS, et al. Interaction between obesity and genetic polymorphisms in the apolipoprotein CIII gene and lipoprotein lipase gene on the risk of hypertriglyceridemia in Chinese. Hum Genet 1997; 100: 327-333.

25. Hong SH, Park WH, Lee CC, Song JH, Kim JQ. Association between genetic variations of apo AI-CIII-AIV cluster gene and hypertriglyceridemic subjects. Clin Chem 1997; 43: 13-17.

26. Huang MC, Wang TN, Liu YL, Pa TH, Tu HP, Huang YC, et al. Effect of SstI polymorphism of the apolipoprotein CIII gene and environmental factors on risks of hypertriglyceridemia in Taiwan aborigines. Circ J 2006; 70: 1030-1036.

27. Russo GT, Meigs JB, Cupples LA, Demissie S, Otvos JD, Wilson PW, et al. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis 2001; 158: 173-181.

28. Smith CE, Tucker KL, Scott TM, Van Rompay M, Mattei J, Lai CQ, et al. Apolipoprotein C3 polymorphisms, cognitive function and diabetes in Caribbean origin Hispanics. PLoS One 2009; 4: e5465.

29. Shoulders CC, Harry PJ, Lagrost L, White SE, Shah NF, North JD, et al. Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. Atherosclerosis 1991; 87: 239-247.

30. Dalinga-Thie GM, Bu XD, van Linde-Sibenius TM, Rotter JI, Lusis AJ, de Bruin TW. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 1996; 37: 136-147.

31. Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77: 43-50.

32. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985; 75: 384-390.

33. Kinnunen PK, Ehnolm C. Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett 1976; 65: 354-357.

34. Sundaram M, Zhong S, Bou KM, Links PH, Zhao Y, Iqbal J, et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res 2010; 51: 150-161.

35. Price TM, O’Brien SN, Welter BH, George R, Anandjiwala J, Kilgore M. Estrogen regulation of adipose tissue lipoprotein lipase - possible mechanism of body fat distribution. Am J Obstet Gynecol 1998; 178: 101-107.

36. Saha N, Heng CK, Mozoomdar BP, Reuben EM, Soh HT, Low PS, et al. Racial variation of factor VII activity and antigen levels and their correlates in healthy Chinese and Indians at low and high risk for coronary artery disease. Atherosclerosis 1995; 117: 33-42.

37. McGladdery SH, Pimstone SN, Clee SM, Bowden JF, Hayden MR, Frohlich JJ. Common mutations in the lipoprotein lipase gene (LPL): effects on HDL-cholesterol levels in a Chinese Canadian population. Atherosclerosis 2001; 156: 401-407.

38. Cai HJ, Li ZX, Yang SM. Serum high density lipoprotein cholesterol levels in Chinese healthy subjects and patients with certain diseases. Atherosclerosis 1982; 43: 197-207.

Acknowledgments

Research supported by grants from Sichuan Program for Sciences and Technology (grant #2008HH0008 to D.Z. Fang) and the Program for New Century Excellent Talents in Universities in China (grant #NCET-04-0863 to D.Z. Fang).

Address for correspondence: D.Z. Fang, Department of Biochemistry and Molecular Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, China. Fax: [phone]. E-mail: [e-mail]

Received October 23, 2010. Accepted April 29, 2011. Available online May 20, 2011. Published June 13, 2011.

The Brazilian Journal of Medical and Biological Research is partially financed by

References

• 1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
• 2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
• 3. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117: 3002-3009.
• 4. Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 2009; 5: 757-765.
• 5. Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 2004; 110: 2824-2830.
• 6. Hsia SH, Pan D, Berookim P, Lee ML. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol 2006; 98: 1047-1052.
• 7. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006; 22: 913-927.
• 8. Goswami B, Rajappa M, Mallika V, Kumar S, Shukla DK. Apo-B/apo-AI ratio: a better discriminator of coronary artery disease risk than other conventional lipid ratios in Indian patients with acute myocardial infarction. Acta Cardiol 2008; 63: 749-755.
• 9. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372: 224-233.
• 10. Liem AH, van de Woestijne AP, Roeters van Lennep HW, Zwinderman AH, van der Steeg WA, Jukema JW. ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients. Curr Med Res Opin 2008; 24: 359-364.
• 11. Parks EJ, Hellerstein MK. Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 2000; 71: 412-433.
• 12. Kasim-Karakas SE, Almario RU, Mueller WM, Peerson J. Changes in plasma lipoproteins during low-fat, high-carbohydrate diets: effects of energy intake. Am J Clin Nutr 2000; 71: 1439-1447.
• 13. Satoh H, Nishino T, Tomita K, Tsutsui H. Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men. Circ J 2006; 70: 227-231.
• 14. Lee MM, Wu-Williams A, Whittemore AS, Zheng S, Gallagher R, Teh CZ, et al. Comparison of dietary habits, physical activity and body size among Chinese in North America and China. Int J Epidemiol 1994; 23: 984-990.
• 15. Chen Z, Shu XO, Yang G, Li H, Li Q, Gao YT, et al. Nutrient intake among Chinese women living in Shanghai, China. Br J Nutr 2006; 96: 393-399.
• 16. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001; 12: 297-304.
• 17. Dallongeville J, Meirhaeghe A, Cottel D, Fruchart JC, Amouyel P, Helbecque N. Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. Atherosclerosis 2000; 150: 149-157.
• 18. Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 2008; 8: 228-236.
• 19. Hallman DM, Srinivasan SR, Chen W, Boerwinkle E, Berenson GS. Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study. Metabolism 2006; 55: 1574-1581.
• 20. Talmud PJ, Humphries SE. Apolipoprotein C-III gene variation and dyslipidaemia. Curr Opin Lipidol 1997; 8: 154-158.
• 21. Chhabra S, Narang R, Krishnan LR, Vasisht S, Agarwal DP, Srivastava LM, et al. Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC Genet 2002; 3: 9.
• 22. Ahn YI, Valdez R, Reddy AP, Cole SA, Weiss KM, Ferrell RE. DNA polymorphisms of the apolipoprotein AI/CIII/AIV gene cluster influence plasma cholesterol and triglyceride levels in the Mayans of the Yucatan Peninsula, Mexico. Hum Hered 1991; 41: 281-289.
• 23. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 1993; 100: 157-169.
• 24. Ko YL, Ko YS, Wu SM, Teng MS, Chen FR, Hsu TS, et al. Interaction between obesity and genetic polymorphisms in the apolipoprotein CIII gene and lipoprotein lipase gene on the risk of hypertriglyceridemia in Chinese. Hum Genet 1997; 100: 327-333.
• 25. Hong SH, Park WH, Lee CC, Song JH, Kim JQ. Association between genetic variations of apo AI-CIII-AIV cluster gene and hypertriglyceridemic subjects. Clin Chem 1997; 43: 13-17.
• 26. Huang MC, Wang TN, Liu YL, Pa TH, Tu HP, Huang YC, et al. Effect of SstI polymorphism of the apolipoprotein CIII gene and environmental factors on risks of hypertriglyceridemia in Taiwan aborigines. Circ J 2006; 70: 1030-1036.
• 27. Russo GT, Meigs JB, Cupples LA, Demissie S, Otvos JD, Wilson PW, et al. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis 2001; 158: 173-181.
• 28. Smith CE, Tucker KL, Scott TM, Van Rompay M, Mattei J, Lai CQ, et al. Apolipoprotein C3 polymorphisms, cognitive function and diabetes in Caribbean origin Hispanics. PLoS One 2009; 4: e5465.
• 29. Shoulders CC, Harry PJ, Lagrost L, White SE, Shah NF, North JD, et al. Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. Atherosclerosis 1991; 87: 239-247.
• 30. Dalinga-Thie GM, Bu XD, van Linde-Sibenius TM, Rotter JI, Lusis AJ, de Bruin TW. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 1996; 37: 136-147.
• 31. Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77: 43-50.
• 32. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985; 75: 384-390.
• 33. Kinnunen PK, Ehnolm C. Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett 1976; 65: 354-357.
• 34. Sundaram M, Zhong S, Bou KM, Links PH, Zhao Y, Iqbal J, et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res 2010; 51: 150-161.
• 36. Saha N, Heng CK, Mozoomdar BP, Reuben EM, Soh HT, Low PS, et al. Racial variation of factor VII activity and antigen levels and their correlates in healthy Chinese and Indians at low and high risk for coronary artery disease. Atherosclerosis 1995; 117: 33-42.
• 37. McGladdery SH, Pimstone SN, Clee SM, Bowden JF, Hayden MR, Frohlich JJ. Common mutations in the lipoprotein lipase gene (LPL): effects on HDL-cholesterol levels in a Chinese Canadian population. Atherosclerosis 2001; 156: 401-407.
• 38. Cai HJ, Li ZX, Yang SM. Serum high density lipoprotein cholesterol levels in Chinese healthy subjects and patients with certain diseases. Atherosclerosis 1982; 43: 197-207.

Correspondence and Footnotes

Publication Dates

• Publication in this collection
  11 Nov 2011
• Date of issue
  June 2011

History

• Received
  23 Oct 2010
• Accepted
  29 Apr 2011